Greg Verdine will have many new C-suite friends at fungus biotech LifeMine after GSK-fueled $175M round
A year after securing funds from Rick Klausner and adding Nobel laureate William Kaelin to the board, fungus-focused LifeMine Therapeutics is ready to reveal the Big Pharma partner it’s spent more than two years courting, with Hal Barron involved, and the dry powder it’s been reeling in since October.
The biotech is headed into its next chapter with GlaxoSmithKline, and another “half a dozen” pharmas are in the hopper for potential partnerships, co-founder and CEO Greg Verdine told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.